2) Not entirely sure which drug this refers to, but Scheibenbogen previously talked about doing a trial targeting plasma cells that produce antibodies, so it could be Isatuximab (which targets the cell marker CD38, the same as Daratumumab).
December 17, 2025 at 3:02 PM
2) Not entirely sure which drug this refers to, but Scheibenbogen previously talked about doing a trial targeting plasma cells that produce antibodies, so it could be Isatuximab (which targets the cell marker CD38, the same as Daratumumab).
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
December 24, 2024 at 3:07 AM
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...
#mmsm #Hematology
www.onclive.com/view/isatuxi...
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
www.onclive.com
January 22, 2025 at 4:39 PM
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...
#mmsm #Hematology
www.onclive.com/view/isatuxi...
I’m also NED after my current treatment ends in 2 weeks. New treatment protocol for recurring Multiple Myeloma
3 drugs-Pomalyst-Isatuximab-
Dexamethasone, recently approved. Provided better results than my previous SCT. Cancer research funding at its
Best. GOP does not believe in science.
3 drugs-Pomalyst-Isatuximab-
Dexamethasone, recently approved. Provided better results than my previous SCT. Cancer research funding at its
Best. GOP does not believe in science.
February 12, 2025 at 3:54 PM
I’m also NED after my current treatment ends in 2 weeks. New treatment protocol for recurring Multiple Myeloma
3 drugs-Pomalyst-Isatuximab-
Dexamethasone, recently approved. Provided better results than my previous SCT. Cancer research funding at its
Best. GOP does not believe in science.
3 drugs-Pomalyst-Isatuximab-
Dexamethasone, recently approved. Provided better results than my previous SCT. Cancer research funding at its
Best. GOP does not believe in science.
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with relapsed or refractory multiple myeloma, according to phase 3 trial results presented at #EHA2025. #mmsm shorturl.at/CyQVS
July 1, 2025 at 5:32 PM
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with relapsed or refractory multiple myeloma, according to phase 3 trial results presented at #EHA2025. #mmsm shorturl.at/CyQVS
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
September 25, 2025 at 3:01 PM
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayocliniccancer.bsky.social #mmsm #oncology
www.onclive.com/view/subcuta...
www.onclive.com/view/subcuta...
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.
www.onclive.com
January 9, 2025 at 4:21 PM
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayocliniccancer.bsky.social #mmsm #oncology
www.onclive.com/view/subcuta...
www.onclive.com/view/subcuta...
Combining isatuximab and cemiplimab led to a promising 51% complete response rate in relapsed NK/T-cell lymphoma patients.
by Kim SJ, Lim JQ (...) Kim WS et 17 al. in Blood #MedSky
📖 read the article:
by Kim SJ, Lim JQ (...) Kim WS et 17 al. in Blood #MedSky
📖 read the article:
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
Key Points. Isatuximab and cemiplimab combined therapy shows durable responses and manageable safety in relapsed/refractory NK/T-cell lymphoma.Structural v
ashpublications.org
March 21, 2025 at 12:53 PM
Combining isatuximab and cemiplimab led to a promising 51% complete response rate in relapsed NK/T-cell lymphoma patients.
by Kim SJ, Lim JQ (...) Kim WS et 17 al. in Blood #MedSky
📖 read the article:
by Kim SJ, Lim JQ (...) Kim WS et 17 al. in Blood #MedSky
📖 read the article:
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025, covered by @cancertherapyadv.bsky.social.
Data Support Use of Isatuximab via On-Body Injector, Researcher Says - Hematology Advisor
“I believe IRAKLIA is going to allow us to use isatuximab in its subcu formulation with this OBI , maybe tomorrow or the day after, in our practice,” said Xavier Leleu, MD, PhD.
bit.ly
August 2, 2025 at 6:35 PM
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025, covered by @cancertherapyadv.bsky.social.
Isatuximab monotherapy shows significant clinical activity in R/R AL #amyloidosis:
• 77.1% overall hematologic response rate
• 1.1 months median time to response
• 57% cardiac response rate
From @bloodjournals.hematology.org Read more: ➡️ https://bit.ly/4qNGBBR
#Hematology #ClinicalTrials #MedSky
• 77.1% overall hematologic response rate
• 1.1 months median time to response
• 57% cardiac response rate
From @bloodjournals.hematology.org Read more: ➡️ https://bit.ly/4qNGBBR
#Hematology #ClinicalTrials #MedSky
Isatuximab Demonstrated Promising Efficacy in R/R Light Chain Amyloidosis
Researchers determined isatuximab monotherapy resulted in promising hematologic response rates with a good safety profile among patients with R/R AL amyloidosis.
bit.ly
February 21, 2026 at 7:52 PM
Isatuximab monotherapy shows significant clinical activity in R/R AL #amyloidosis:
• 77.1% overall hematologic response rate
• 1.1 months median time to response
• 57% cardiac response rate
From @bloodjournals.hematology.org Read more: ➡️ https://bit.ly/4qNGBBR
#Hematology #ClinicalTrials #MedSky
• 77.1% overall hematologic response rate
• 1.1 months median time to response
• 57% cardiac response rate
From @bloodjournals.hematology.org Read more: ➡️ https://bit.ly/4qNGBBR
#Hematology #ClinicalTrials #MedSky
JUST OUT #ASH24
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
December 9, 2024 at 7:17 PM
JUST OUT #ASH24
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
Even if a patient switches status from MRD negative to MRD positive, IMROZ study data at #ASH24 shows treatment with Isatuximab and Lenalidomide as maintenance therapy can help delay disease progression.
December 9, 2024 at 8:27 PM
Even if a patient switches status from MRD negative to MRD positive, IMROZ study data at #ASH24 shows treatment with Isatuximab and Lenalidomide as maintenance therapy can help delay disease progression.
A new trial shows isatuximab delivered subcutaneously is as effective and safe as the intravenous method for multiple myeloma patients.
by Ailawadhi S, Špička I (...) Moreau P et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00744
by Ailawadhi S, Špička I (...) Moreau P et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00744
August 10, 2025 at 10:36 AM
A new trial shows isatuximab delivered subcutaneously is as effective and safe as the intravenous method for multiple myeloma patients.
by Ailawadhi S, Špička I (...) Moreau P et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00744
by Ailawadhi S, Špička I (...) Moreau P et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00744
New from #StemCellEvidence:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
by Mai et al.
www.stemcellevidence.com/alerts/artic...
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
by Mai et al.
www.stemcellevidence.com/alerts/artic...
February 6, 2025 at 1:13 PM
New from #StemCellEvidence:
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
by Mai et al.
www.stemcellevidence.com/alerts/artic...
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
by Mai et al.
www.stemcellevidence.com/alerts/artic...
Dr. Terri Parker presented results from the phase 2 trial of
SWOG 1702 of Isatuximab in relapsed AL #amyloidosis was well tolerated and showed high rates of hematologic response #ASH24. ash.confex.com/ash/2024/web...
@yale-hematology.bsky.social @ash-hematology.bsky.social
SWOG 1702 of Isatuximab in relapsed AL #amyloidosis was well tolerated and showed high rates of hematologic response #ASH24. ash.confex.com/ash/2024/web...
@yale-hematology.bsky.social @ash-hematology.bsky.social
December 10, 2024 at 7:32 PM
Dr. Terri Parker presented results from the phase 2 trial of
SWOG 1702 of Isatuximab in relapsed AL #amyloidosis was well tolerated and showed high rates of hematologic response #ASH24. ash.confex.com/ash/2024/web...
@yale-hematology.bsky.social @ash-hematology.bsky.social
SWOG 1702 of Isatuximab in relapsed AL #amyloidosis was well tolerated and showed high rates of hematologic response #ASH24. ash.confex.com/ash/2024/web...
@yale-hematology.bsky.social @ash-hematology.bsky.social
SMC declines isatuximab frontline myeloma indication after sponsor non-submission
https://www.mattheneus.com/editorial/smc-isatuximab-non-submission-ndmm-autologous-transplant-2026-03-09
#HTA #EvidenceSynthesis #HealthEconomics
https://www.mattheneus.com/editorial/smc-isatuximab-non-submission-ndmm-autologous-transplant-2026-03-09
#HTA #EvidenceSynthesis #HealthEconomics
March 14, 2026 at 1:19 PM
SMC declines isatuximab frontline myeloma indication after sponsor non-submission
https://www.mattheneus.com/editorial/smc-isatuximab-non-submission-ndmm-autologous-transplant-2026-03-09
#HTA #EvidenceSynthesis #HealthEconomics
https://www.mattheneus.com/editorial/smc-isatuximab-non-submission-ndmm-autologous-transplant-2026-03-09
#HTA #EvidenceSynthesis #HealthEconomics
CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma #mmsm #oncology www.onclive.com/view/chmp-re...
CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma
CHMP issues positive opinion for isatuximab plus VRd in transplant-eligible, newly diagnosed multiple myeloma.
www.onclive.com
June 23, 2025 at 3:19 PM
CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma #mmsm #oncology www.onclive.com/view/chmp-re...
SARCLISA (isatuximab) is being studied with an on-body injector that delivers the drug subcutaneously over 12-15 minutes—no IV needed. A promising new way to make treatment more convenient! #AskTheIMF
August 23, 2025 at 2:25 PM
SARCLISA (isatuximab) is being studied with an on-body injector that delivers the drug subcutaneously over 12-15 minutes—no IV needed. A promising new way to make treatment more convenient! #AskTheIMF
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025.
bit.ly/46jn1qB
bit.ly/46jn1qB
Data Support Use of Isatuximab via On-Body Injector, Researcher Says - Hematology Advisor
“I believe IRAKLIA is going to allow us to use isatuximab in its subcu formulation with this OBI , maybe tomorrow or the day after, in our practice,” said Xavier Leleu, MD, PhD.
bit.ly
July 29, 2025 at 7:09 PM
Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025.
bit.ly/46jn1qB
bit.ly/46jn1qB
#IDBoardReview
49 yo woman with PMH relapsed multiple myeloma tx with Isatuximab, pomalyst, & dex p/w 3 d of fever, AMS, dense LLL pna . What is the dx?
A. HSV pna
B. Bacterial pna w/encapsulated org
C. Reactivation TB
D. Aspergillosis
www.ppidjournal.com/quiz/multipl...
49 yo woman with PMH relapsed multiple myeloma tx with Isatuximab, pomalyst, & dex p/w 3 d of fever, AMS, dense LLL pna . What is the dx?
A. HSV pna
B. Bacterial pna w/encapsulated org
C. Reactivation TB
D. Aspergillosis
www.ppidjournal.com/quiz/multipl...
Board Review | Multiple Myeloma
1. 49 yo woman with PMH relapsed refractory IgG Lamba Multiple Myeloma, most recently treated with Isatuximab, Pomalyst, dexamethasone presents to the hospital with 3 days of altered mental status,…
www.ppidjournal.com
March 19, 2025 at 12:00 PM
#IDBoardReview
49 yo woman with PMH relapsed multiple myeloma tx with Isatuximab, pomalyst, & dex p/w 3 d of fever, AMS, dense LLL pna . What is the dx?
A. HSV pna
B. Bacterial pna w/encapsulated org
C. Reactivation TB
D. Aspergillosis
www.ppidjournal.com/quiz/multipl...
49 yo woman with PMH relapsed multiple myeloma tx with Isatuximab, pomalyst, & dex p/w 3 d of fever, AMS, dense LLL pna . What is the dx?
A. HSV pna
B. Bacterial pna w/encapsulated org
C. Reactivation TB
D. Aspergillosis
www.ppidjournal.com/quiz/multipl...
L'European Commission a approuvé l’ #isatuximab associé à la VRd dans le #MyélomeMultiple nouvellement diagnostiqué admissible à une greffe.
#Oncology
www.onclive.com/view/isatuxi...
#Oncology
www.onclive.com/view/isatuxi...
Isatuximab Plus VRd Approved in Europe for Transplant-Eligible Newly Diagnosed Multiple Myeloma
The European Commission has approved isatuximab plus VRd in transplant-eligible newly diagnosed multiple myeloma.
www.onclive.com
July 25, 2025 at 4:40 PM
L'European Commission a approuvé l’ #isatuximab associé à la VRd dans le #MyélomeMultiple nouvellement diagnostiqué admissible à une greffe.
#Oncology
www.onclive.com/view/isatuxi...
#Oncology
www.onclive.com/view/isatuxi...
NICE Technology Appraisal Guideline [TA1194]: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. www.nice.org.uk/guidance/ta1...
Overview | Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | Guidance | NICE
www.nice.org.uk
September 25, 2026 at 10:16 AM
NICE Technology Appraisal Guideline [TA1194]: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. www.nice.org.uk/guidance/ta1...
The combined use of isatuximab and cemiplimab showed persistent antitumor activity alongside a manageable safety profile among patients with R/R ENKTL. From @hematologyadvisor.bsky.social.
https://bit.ly/4qaQavt
#lymsm
https://bit.ly/4qaQavt
#lymsm
Combination Isatuximab and Cemiplimab Effective, Safe in Treating R/R ENKTL - Oncology Nurse Advisor
Researchers sought to determine whether isatuximab and cemiplimab would be safe and effective for patients with relapsed/refractory extranodal NK/T-cell lymphoma.
bit.ly
October 19, 2025 at 7:24 PM
The combined use of isatuximab and cemiplimab showed persistent antitumor activity alongside a manageable safety profile among patients with R/R ENKTL. From @hematologyadvisor.bsky.social.
https://bit.ly/4qaQavt
#lymsm
https://bit.ly/4qaQavt
#lymsm
Subcutaneous administration of isatuximab using an OBI demonstrated similar response rates as the IV formulation regardless of the LOT among patients with R/R #multipleMyeloma. Presented at #IMS2025.
https://bit.ly/46PsR2D
https://bit.ly/46PsR2D
Subcutaneous Isatuximab Effective Across All Lines of Therapy in RRMM
Researchers determined subcutaneous isatuximab is an effective therapy for patients with RRMM across all lines of therapy.
bit.ly
September 22, 2025 at 10:48 PM
Subcutaneous administration of isatuximab using an OBI demonstrated similar response rates as the IV formulation regardless of the LOT among patients with R/R #multipleMyeloma. Presented at #IMS2025.
https://bit.ly/46PsR2D
https://bit.ly/46PsR2D